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of bladder cancer by targeting the LOXL4 gene
and the Oxidative Stress pathway
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Background: Chemoresistance is a major obstacle to the curative cancer chemotherapy and presents one of the
most formidable challenges in both research and management of cancer.
Results: From the detailed studies of a multi-chemosensitive (5637) versus a chemoresistant (H-bc) bladder cancer
cell lines, we showed that miR-193a-3p [GenBank: NR_029710.1] promotes the multi-chemoresistance of bladder
cancer cells. We further demonstrated that lysyl oxidase-like 4 (LOXL4) gene [GenBank: NM_032211.6] is a direct
target of miR-193a-3p and executes the former’s impact on bladder cancer chemoresistance. The Oxidative Stress
pathway activity is drastically affected by a forced reversal of miR-193a-3p or LOXL4 levels in cell and may act at the
downstream of LOXL4 gene to relay the miR-193a-3p’s impact on the multi-chemoresistance in both cultured cells
and the tumor xenografts in nude mice.
Conclusions: In addition to a new mechanistic insight, our results provide a set of the essential genes in this newly
identified miR-193a-3p/LOXL4/Oxidative Stress axis as the diagnostic targets for a guided anti-bladder cancer
chemotherapy.
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Bladder cancer (BCa) is the second most frequent type of
cancer in male around the world [1]. It is highly refractory
to the drug therapy, frequently recurs in a more aggressive
form after the initial surgical eradication, and therefore
regarded as one of the most costly and difficult types of
cancer to be contained [2]. Chemoresistance prevails in
cancer clinic and is hard to be predicted in advance, pre-
venting the effective cancer chemotherapy [3]. Despite
years of intensive efforts, our mechanistic understanding
of cancer chemoresistance remains elusive.
MicroRNAs (miRs) are a group of RNA species being
around 22 nucleotides length and regulate expression of* Correspondence: jdzhu0105@vip.163.com
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unless otherwise stated.the protein coding genes in all physiological conditions
of higher eukaryotes via its repressing effect at both
translability and stability levels of mRNAs in a sequence
specific fashion [4]. Among more than 2,000 known hu-
man miRs, several dozens are aberrantly expressed in
cancer and have the proven roles in both initiation and
progression of cancer [5]. The miRs upregulated in can-
cer cells often have the oncogenic role, and the well-
known examples of this class are miR-10b, miR-17-92,
miR-122 and miR-155 [6]. Conversely, there are miRs
having the negative role in regulation of cell proliferation
and are often down-regulated in cancer cells, such as
let-7c, miR-10b, miR-15a, miR-31, miR-34, miR-145,
miR-223 [7]. The miR’s prospects as the drug-specific
target [8] and biomarker [9] have gained a great atten-
tion in recent years. The panel of miRs implicated in the
initiation and maintenance of the cancer chemoresis-
tance has also been reported [10], and the noticeabletd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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miR-181, and miR-199a-5p [11].
The first indication that miR-193a-3p might be in-
volved in tumor suppression was the observation that it
was silenced by DNA methylation during oral carcino-
genesis [12]. Dysregulation of miR-193a-3p was also re-
ported in other types of cancer, such as non-small cell
lung cancer (NSCLC) [13], prostate cancer [14], breast
cancer [15], Head and Neck Squamous Cell Carcinomas
[16], and colorectal cancer [17]. The carcinogenic impact
of miR-193a-3p has been attributed to its repression of
c-Kit [18] and the PTEN/PI3K signaling pathway in
acute myeloid leukemia [19], of KRAS and PLAU in
colon cancer [20], of PLAU [21] and EGFR-driven cell-
cycle network proteins [22] in breast cancer, of ARH-
GAP19, CCND1, ERBB4, KRAS and Mcl-1 in epithelial
ovarian cancer [23], of PLAU in hepatocellular carcin-
oma (HCC) [24], and of Mcl-1 in NSCLC [25]. MiR-
193a-3p also induces an accumulation of intracellular
reactive oxygen species (ROS) and DNA damage in can-
cer cells via targeting Mcl-1 [26]. It was recently
reported to suppress NSCLC metastasis through down-
regulation of the ERBB4/PIK3R3/mTOR/S6K2 signaling
pathway [27]. In contrast, several studies reported an
oncogenic role for miR-193a-3p. For example, miR-
193a-3p was shown to promote in vivo tumorigenesis of
metastatic medullary thyroid carcinoma [28], and to en-
hance both tumor growth in nude mice and chemoresis-
tance of HCC by targeting of the SRSF2 gene [29].
We show here that miR-193a-3p promotes the BCa
multi-drug resistance phenotype via its repression of the
lysyl oxidase-like 4 (LOXL4) gene, a newly identified dir-
ect target of miR-193a-3p. The LOXL4 protein is an im-
portant member of the lysyl oxidase (an extracellular
copper-dependent amine oxidase) family that catalyzes
the first step of the crosslinks between collagens and
elastin during the biogenesis of connective tissue and is
frequently deregulated in cancer. Mutations in the cod-
ing sequences of LOXL4 gene have also been reported
in various types of cancer from the cancer genomic
studies: COSMIC [http://cancer.sanger.ac.uk]. We also
show here that the Oxidative stress (OS) pathway is the
predominant pathway affected by miR-193a-3p via its
repression of LOXL4 expression.
Results
The miR-193a-3p level was higher in the chemoresistant
(H-bc and UM-UC-3) than the chemosensitive (5637) BCa
cell lines
The dose required for 50% cells killed (IC50) after a
72 hours drug treatment by Pirarubicin(Pi), Paclitaxel
(Pa), Adriamycin(Ad), Cisplatin(Ci) or Epirubicin Hydro-
chloride(EH) were determined in the following five BCa
cell lines: 5637, T24, Biu87, H-bc and UM-UC-3. Judgedby the fold difference over the lowest IC50, 5637 was the
most multi-chemosensitive, while H-bc and UM-UC-3
were the most resistant cell lines (Figure 1A). Revealed
by both a sequencing based miRomic analysis (not
shown) and the qRT-PCR validation, the miR-193a-3p
level was over 100 folds higher in both H-bc and UM-
UC-3 than in 5637 cells (Figure 1B and C). All these
observations suggest that miR-193a-3p may have a pro-
moting role in the BCa chemoresistance as previously
reported in the 5-FU resistance of HCC [29].
LOXL4 mRNA is a direct target of miR-193a-3p in BCa cells
Any a given microRNA may regulate the expression of
up to several hundred genes at the post-transcriptional
level in both cellular content-dependent and sequence-
specific manners. Besides SRSF2 [29], miR-193a-3p’s in-
fluence on the cancer chemoresistance is expected to be
accomplished via repression of its other targets. To this
end, we checked the level of 359 Targetscan (http://
www.targetscan.org/)-predicted genes in the RNA-seq
datasets (the RNA-seq omic data, not shown) of 5637,
UM-UC-3 and H-bc cells. LOXL4 is one of several
dozen genes that differentially expresses in a pattern op-
posite to the miR-193a-3p’s. Further qRT-PCR and
Western analyses showed that LOXL4 level is signifi-
cantly higher in 5637 than in H-bc cells at both mRNA
(RNA-seq based omic analysis: 1.00:0.08, and the qRT-
PCR analysis: 1.00:0.09) and protein levels (Western ana-
lysis: 1.00:0.54, Figure 2). The LOXL4 expression in
another multi-chemoresistant cell line, UM-UC-3 cells
was at an undetectable level (not shown).
We further determined the LOXL4 level in both miR-
193a-3p mimic transfected 5637 and the antagomiR trans-
fected H-bc cells versus the mock transfected. In parallel
with the changes of the miR-193a-3p level (Figure 3A),
a miR-193a-3p mimic transfection brought down the
LOXL4 mRNA level by nearly 70% (Figure 3B) and the
protein level by 58% (Figure 3C) in 5637 cells. As ex-
pected, a miR-193a-3p antagomiR transfection raised the
mRNA level of LOXL4 by over 37 folds (Figure 3B) and
the protein level by 84% in H-bc cells (Figure 3C).
To conclude that LOXL4 gene is a direct target of
miR-193a-3p, we put the wild type or mutant 3′-UTR
region (1325 bp) at the downstream of the firefly lucifer-
ase gene of pGL3 vector (Promega) to create pGL3-
LOXL4 UTR WT and the PGL3-LOXL4 UTR Mut,
respectively (Figure 3D). Both constructs and pGL3 were
transfected into 5637 and H-bc cells respectively, to de-
termine whether the chemoresistance associated expres-
sion of miR-193a-3p in BCa cells is indeed functional.
pGL3-LOXL4 UTR WT but not other two reporter con-
structs gave a significantly higher luciferase activity in
5637 than H-bc cells (Figure 3E). Furthermore, the lucif-
erase activity of pGL3-LOXL4-UTR WT but not other
Figure 1 The miR-193a-3p expression differs in the chemoresistance distinct bladder cancer cell lines. Relative IC50 values (fold) of BCa
cell lines to five chemotherapeutics with the lowest IC50 (5637 cell line) as a reference (A). The relative miR-193a-3p level (fold) in BCa cell lines by
both miR-seq and qRT-PCR analyses is shown in Table (B) and by qRT-PCR in plot (C).
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and raised by the antagomiR transfection in H-bc cells
(Figure 3D). Getting all these together, LOXL4 is indeed,
a direct target of miR-193a-3p and may execute the
miR-193a-3p’s effect on the BCa chemoresistance.
A siRNA mediated LOXL4 repression essentially reproduced
the miR-193a-3p mimic’s effect on the chemoresistant state
of 5637 cells
To explore the LOXL4 role in the BCa chemoresistance,
we transfected 5637 cells with the miR-193a-3p mimic and
the siRNAs of SRSF2 and LOXL4, respectively, and assayed
the cell death triggered by an IC50 dosed drug. The cell
death triggered by all the five drugs was significantly re-
duced in the miR-193a-3p mimic transfected 5637 cells
(Figure 4A). In parallel with the reduction of both target
mRNA and protein levels (Figure 4B and C), the siRNA
mediated LOXL4 repression reduced the cell death trig-
gered by four of five drugs, excluding Ad, while the siRNA
mediated SRSF2 repression relieved the cell death triggered
by four drugs, excluding Pi instead (Figure 4A). TheseFigure 2 The LOXL4 level is higher in 5637 than in H-bc cells. The rela
summarized in table (A), analyzed by Western analysis (B), by miR-seq andobservations suggest that LOXL4 and SRSF2 have signifi-
cantly overlapped but distinguished roles in execution of
the miR-193a-3p’s impact on the BCa chemoresistance in a
drug-specific fashion. Furthermore, an additive (or synergis-
tic) effect on both EH and Ad triggered cell death, but not
on the other drugs were revealed in 5637 cells co-
transfected by both siRNAs (Figure 4A). Essentially as ex-
pected, a miR-193a-3p antagomiR transfection sensitized
H-bc cells to the cell death triggered by four drugs, exclud-
ing Ci (Figure 4D). As a measure of the successful transfec-
tion, the level of both LOXL4 and SRSF2 mRNAs was
altered in a predicted direction in antagomiR transfected
cells (Figure 4E). In line with its negative effect on che-
moresistance, a siRNA mediated LOXL4 repression low-
ered the percentage of apoptotic cells from 2.35% to 1.81%,
an effect was not seen in the mimic transfected 5637 cells
(Figure 4F). Despite this difference, LOXL4 indeed plays an
essential part in the miR-193a-3p’s effect on the multi-
chemoresistance of BCa cells, except for the Ad resistance.
It is surprising to find a significant discrepancy be-
tween the mRNA level (by qRT-PCR) and protein leveltive level (fold) of the LOXL4 gene in 5637 versus H-bc cells
qRT-PCR analyses in plot (C).
Figure 3 The LOXL4 is a direct target of miR-193a-3p in BCa cells. The level of miR-193a-3p (A), the LOXL4 mRNA l (B) and protein (C) in
the miR-193a-3p mimic (3 PM) transfected 5637 cells and the miR-193a-3p antagomiR (3PA) transfected H-bc cells versus the negative control
(NC), determined by qRT-PCR or Western analyses. D, The sequences (the wild-type in shadow and mutant in red) in UTR region of LOXL4 gene
targeted by miR-193a-3p. E, The relative luciferase activity (fold) of the reporter with wild-type (WT) or mutant (Mut) LOXL4-UTR or with no UTR
(Vec) were determined in the miR-193a-3p mimic (in 5637) or antagomir (in H-bc) or Mock transfected BCa cells. The Renilla luciferase activity of a
co-transfected control plasmid was used to control the transfection efficacy. The representative results from three independent experiments
shown. Error bars represent s.e.m. **P < 0.01; by Student’s t-test.
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tered by miR-193-3p mimic or antagomiR, the alteration
of the protein level is far limited than that of mRNA. It
has been established that the relative contribution of a
miR mediated translation repression and RNA degrad-
ation promotion to the expression of its target genes is
target gene specific. Indeed, it has been shown that for
highly repressed targets, mRNA destabilization usually
comprised the major component of repression by miRs
[30]. Relevant to this issue, Wu, L et al. have recently
shown that miRs also serves as a surveillance system to
repress the expression of nonsense mRNAs that may
produce harmful truncated proteins [31]. It is thus very
likely that the observed massive reduction/increase of
SRSF2 and LOXL4 mRNA by the mimic (in 5637 cells)/
antagomiR in H-bc cells reflects mainly the changes in
the nonsense transcripts in cells, which can not be trans-
lated to the protein at the first place.
The LOXL4 level was negatively associated with the OS
pathway activity in the content of the BCa
chemoresistance
For the mechanistic insights, we used the Qiagen™ path-
way reporter assay to compare the activities of the
following five chemoresistance associated signalingpathways: DNA damage, Notch, NF-κB, Myc/Max and
Oxidative Stress (OS) pathways in 5637 versus H-bc
cells. The activities of the following three pathways:
DNA damage, NF-κB and myc/max pathways were
higher by no less than 2 folds in 5637 than H-bc cells
(Figure 5A. The activities of these three pathways were
reduced in the miR-193a-3p mimic transfected 5637
(Figure 5B) and elevated in the antagomiR transfected
H-bc cells (Figure 5C), indicating a negative association
of which with the BCa chemoresistance. The opposite was
true for both OS and Notch pathways (Figure 5A-C). We
then compared the pathway activities in the LOXL4 siR-
NAs versus the mock siRNA transfected 5637 cells. Al-
though no or marginal effect on the activities of the DNA
damage, NF-κB and Myc/Max pathways was observed,
both OS and Notch pathways were activated in the
LOXL4 siRNA transfected to a similar extent observed in
the mimic transfected 5637 cells (Figure 5B) with the OS
pathway’s response most drastically, Therefore, the
LOXL4’s role to relay the miR-193a-3p’s effect on the
BCa chemoresistance is principally accomplished via its
effect on the OS pathway. We further measured the
mRNA levels of the genes encoding two master tran-
scription factors in OS pathway: Nrf1 and Nrf2, one
downstream gene of OS pathway: NQO1 [32], and two
Figure 4 The effects of a forced reversal of the miR-193a-3p or LOXL4 levels on the chemoresistance of 5637 and H-bc cells. A, The IC50
dosed drug-triggered cell death of 5637 cells transfected by miR-193a-3p mimic (3 PM) or the gene specific siRNAs versus the negative control
(NC). B, The levels by qRT-PCR of both LOXL4 and SRSF2 mRNAs in the 3 PM, or siRNAs (single or in combination) transfected 5637 cells and the
3PA transfected H-bc cells versus the NC. C, The levels by Western analysis of both LOXL4 and SRSF2 proteins in the siRNA versus the negative
control siRNA (NC) transfected 5637 cells. D, The drug-triggered cell death of the miR-193a-3p antagomiR (3PA) versus the NC transfected H-bc
cells. E, The levels of both LOXL4 and SRSF2 mRNAs and proteins were measured by qPCR and Western analyses in the 3PA versus NC transfected
H-bc cells. F, The effects of the forced reversal of both miR-193a-3p and LOXL4 levels on the apoptosis by FACS analysis of 5637 cells in plot and
in the original. (*,P < 0.05; **,P < 0.01).
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[34] by qRT-PCR analysis. Coincidently, the Nrf1,
Nrf2, NQO1 and SUV39H1 mRNAs were higher in H-
bc than 5637 cells (Figure 5D), and were raised in the
miR-193a-3p mimic and LOXL4 siRNA transfected 5637
cells (Figure 5E), while repressed in the miR-193a-3p
antagomiR transfected H-bc cells (Figure 5F). Although
being slightly lower in H-bc than 5637 cells, the CDC37
level in 5637 cells was also significantly raised by the
LOXL4 siRNA transfection. In conclusion, there is a verystrong biochemical and biological link between the
LOXL4 level and the OS pathway activity in the content
of the BCa chemoresistance.
miR-193a-3p promotes Pa chemoresistance of BCa via
repressing both SRSF2 and LOXL4 expression in BCa
tumor xenografts in nude mice
To minimize the inter-mouse bias, 5637 (1.5 × 107 cells/
site) or H-bc (0.7 × 107 cells/site) cells were subcutane-
ously injected at two back sites of six mice each. An
Figure 5 The effects of the forced reversal of both miR-193a-3p and LOXL4 levels on the activity of the signaling pathways in 5637
versus H-bc cells. A, The relative activities (in mean ± S.D) of five indicated pathways in 5637 versus H-bc cells. B, The relative pathway activities
in the LOXL4 siRNA or miR-193a-3p mimic (3 PM) versus the NC transfected 5637 cells. C, The relative pathway activities in the miR-193a-3p
antagomiR (3PA) versus the NC transfected H-bc cells. D, The level of the OS pathway related mRNAs in 5637 and H-bc cells. E, The level of the
OS pathway related mRNAs in the miR-193a-3p mimic or siRNA versus the NC transfected 5637 cell. F, The level of the OS pathway related mRNA
s in the miR-193a-3p antagomiR versus the NC transfected H-bc cells. (*, p <0.05; **,P < 0.01).
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into the 5637/H-bc derived tumors on the left back of
mice was initiated on the 4th day and repeated four
times once in two days. The intraperitoneal injection of
PBS or Pa was started on day 6th into three mice each in
either 5637 or H-bc groups and repeated four times
once in two days (Figure 6A). The tumor mass was
weighed on day 25th. With half less cells injected, the
H-bc derived tumors were significantly heavier than 5637
derived (0.81 g/0.53 g = 1.53 in tumor weight) (Figure 6C
and D), suggesting a miR-193a’s promoting role in thein vivo tumor growth. This conclusion was supported by
the experiments where both 5637 and H-bc tumor xeno-
grafts were established in the same mice (not show). An
intratumor injection of miR-193a-3p agomiR in compari-
son with the mock into the 5637 cell derived tumor xeno-
graft resulted in a bigger tumor mass of 5637 cell derived
tumor xenografts (0.81/0.53 = 1.53). The reverse was true
from the compatible experiments with the antagomiR in
H-bc tumor mice (0.13/0.40 = 0.33 in tumor weight).
Therefore, the miR-193a-3p is capable to promote the
in vivo BCa tumor growth in nude mice. In a full
Figure 6 The miR-193a-3p’s effect on both the in vivo growth and Pa chemoresistance of 5637 and H-bc derived xenografts in nude
mice. A, The experimental scheme, 5637 cells or H-bc cells were subcutaneously injected at four points at back of each nude mice, respectively.
From the day 4th, PBS, the miR-193a-3p agomiR/antagomiR or the scramble sequence control (Mock) was intratumourly injected into a pair of
5637/H-bc tumors on right back site (NB, the other pair of tumor was injected with the reagents that has nor relevance in this study), respectively,
once every two days for 5 times as indicated. From day 6th, each of three mice for 5637 or H-bc received the intraperitoneal injection of PBS or
Pa once every two days for 5 times, respectively. B, The image of the representative mice with tumors on the day 25th. C, The mean ± SD of
tumor weight of the tumor from same treatment was calculated and plotted, *, p < 0.05, and summarized in table D E, The 5637 or H-bc tumor
tissues from each group were fixed on the same slide and immunostained with the indicated antibodies. Levels of Ki67, SRSF2, and LOXL4
proteins in each indicated tumor tissues were scored and summarized.
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resistant than 5637 cells in cultured cells (Figure 1), an in-
traperitoneal injection of Pa reduced the 5637 tumors
more dramatically than the H-bc tumor: the tumor weight
ratio of the Pa treated over the PBS control is 0.283 (5637)
versus 0.40 (H-bc) (Figure 6D).
We further assayed the levels of SRSF2, LOXL4 and
Ki67 (an indicator for cell proliferation) in the tumor ses-
sions of the Pa-treated versus PBS-treated mice (Figure 6E
and Additional file 1: Figure S1), by the immuno-
histological analysis. The intratumor injection of either
miR-193a-3p’s agomiR (into 5637)/antagomiR (into H-bc
tumor) indeed led the expected changes of both SRSF2
and LOXL4 proteins in tumor tissues (Figure 6E), and
consolidate the conclusion that miR-193a-3p promotes
both the growth and chemoresistance of the BCa cell de-
rived tumor xenografts in nude mice.Discussion
In our previous study, we showed that SRSF2, as a key ex-
ecutor of the miR-193a-3p’s impact on the 5-FU resistance
in HCC [29]. In the present work, LOXL4 as another dir-
ect target of miR-193a-3p has been shown having an active
role in an implementation of the miR-193a-3p’s positive
impact on the BCa chemoresistance (Figures 1, 2 and 3) to
great extent. We have shown that LOXL4 mediated the
miR-193a-3p’s chemoresistance effects to four drugs, but
not the Ad’s (Figure 4A). The drug specific chemoresis-
tance profile mediated by SRSF2 differs with LOXL4 by
that the only drug not affected is EH instead (Figure 4A).
The synergistic action by these two genes was only seen in
the case of the chemoresistance to EH and Ad, respectively
(Figure 4A). Therefore, the miR-193a-3p’s impact on the
BCa chemoresistance is significantly achieved by its target-
ing repression of both LOXL4 and SRSF2 expression.
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quired for a collagen remodeling at the metastatic site of
cancer [35-37]. Expression of LOXL4 can be activated
by hypoxia and is positively associated with the invasive/
metastatic state of breast cancer cells [38]. Its overex-
pression has been suggested as a diagnostic biomarker
[35,36,39] and even a therapeutic target for head and
neck cancer treatment [40]. On the other hand, the
tumor suppressor role of LOXL4 was also reported in
colorectal adenocarcinomas [41]. The disparate state of
the LOXL4 role in carcinogenesis has been attributed to
the aberrant regulation at the level of the alternative
mRNA splicing, the products of which possess either
pro- or anti-oncogenic functions [37]. The silenced state
of the LOXL4 gene by DNA methylation was previously
reported in BCa cells [42]. However, a methyl-capture
seq based methylomic analysis (not shown) showed that
the LOXL4 gene is hypomethylated in 5637, H-bc and
UM-UC-3 cell lines, disregard of the drastic contrast in
its expression (Figure 1). Therefore, the miR-193a-3p
mediated regulation at the post-transcriptional levels
likely has a predominant role in the LOXL4 expression
in BCa multi-chemoresistance (Figure 3A and B).
OS pathway is an important cell defense and survival
pathway. It protects cancer cells from diverse hostile
stimuli, including chemotherapeutics by activating the
transcription of a number of cytoprotective genes [43].
Cancer cells with an elevated level of Nrf2 (the key tran-
scriptional factor of OS pathway) are more resistant to
various chemotherapeutic drugs, including etoposide,
carboplatin, cisplatin, 5-fluorouracil, and doxorubicin
[43]. Besides, ectopic expression of Nrf2 in the low ex-
pressing cancer cell lines renders the cells a resistance to
a variety of anti-cancer agents, whereas siRNA-mediated
inhibition of Nrf2 in cells with high expression levels of
Nrf2 sensitized cell to the drug cytotoxicity [43]. Indeed,
the chemoresistant H-bc cells have a significantly higher
level of both Nrf1 and Nrf2 (Figure 5D) and a higher
OS pathway activity than the chemosensitive 5637 cells
(Figure 5A). Importantly, we showed for the first time
that miR-193a-3p can positively regulates the OS path-
way, most likely achieved by its repressing effect on the
LOXL4 expression (Figure 5B)
A network analysis to link the LOXL4 gene to the OS
pathway was performed by combining the literature
mining with an analysis of the public protein-protein
interaction databases: Wiki-PI [http://severus.dbmi.pitt.
edu/wiki-pi/] and BioGRID 3.2 [http://thebiogrid.org/].
Among 15 proteins that directly interact with LOXL4
protein, three have a reported OS pathway association.
SUV39H1 is a histone methyl transferase, responsible
for the histone H3K9 bi-and tri-methylation [34]. It ac-
tively engages in formation of the transcriptional si-
lenced heterochromatin region in genome. SUV39H1 isstabilized by SirT1, the transcription of which is under
regulation of OS pathway [34] and therefore, maintains
the genome integrity in the stressed cells. CDC37 is a
molecular chaperone that form complex with Hsp90 and
a variety of protein kinases. It is thought to play a critical
role in directing Hsp90 to its target kinases, and this
interaction is destabilized by oxidative stress stimuli for
the cellular apoptosis to occur [33]. ECSIT is an adapter
protein of the Toll-like and IL-1 receptor signaling path-
way that is involved in multiple signal pathways, such as
NF-κB and BMP. It may act as a sensor to protect cells
by activation of protective molecular mechanisms in re-
sponse to Oxidative stresses [44]. Interestingly, the follow-
ing two LOXL4 interacting proteins: EXOC6 and COL2A1
genes are the direct target of the OS pathway suggested by
a Nrf2 centered network analysis: NRF2omic database
[http://nrf2.elte.hu/] [45,46]. The EXOC6 gene encodes a
member of SEC15 family contributing to the docking of
exocytic vesicles with fusion sites on the plasma mem-
brane [47]. COL2A1 encodes the alpha-1 chain of type II
collagen [48], directly interact with the following 8 pro-
teins: 6 components of RTK/MAPK pathway (ANXA5,
DDR1, FGF7, PKD1, FN1 and IGFBP7) and 2 components
(BMP2 and TGFB1) in the TGF-beta pathway. The phos-
phorylation state and activity of Nrf2 are under the control
of both RTK/MAPK and TGF-beta pathways [49]. Indeed,
along with a rise of miR-193a-3p level and reduction of
the LOXL4 level in 5637 cells, the drug-triggered cell
death was rescued (Figure 5). However, we found no evi-
dence for that the force reversal of both miR-193-3p and
SRSF2/LOXL4 levels in 5637 and H-bc cells have a detect-
able effect on the level of Nrf2 and its phosphorylated
form as well as its nuclear-cytoplasmic distribution
(data not shown). Therefore, the effect on the OS path-
way (Figure 5) by miR-193a-3p via repression of LOXL4
seems to be produced by other unknown mechanism(s).
The direct interaction between the LOXL4 protein and
the master transcription factors Nrf1 and Nrf2 in OS
pathway has not been reported so far. However five
LOXL4 integrating protein partners discussed above
may act as the key components of the OS pathway
based cellular response to the damage signals, such as
the chemotherapeutic drugs (Figure 7). It is clear that
further efforts are needed to address how the miR-193a-
3p affected the OS pathway through its repression of
the LOXL4 expression in the content of the BCa
chemoresistance.
Conclusion
In this study, we demonstrated that miR-193a-3p pro-
motes the multi-chemoresistance of BCa via repressing
of the LOXL4 expression and therefore activating the
OS pathway. This study also provided a new set of genes
in this newly identified miR-193a-3p/LOXL4/Oxidative
Figure 7 A Simplified interaction map between the LOXL4 protein with the OS pathway by both protein-protein interaction analysis
and literature mining. The red solid lines specify a direct physical interaction between the LOXL4 protein and the indicated proteins. The green
arrow lines indicate transcriptional activation by the OS pathway. The green dashed arrow-lines signify the impact on OS pathway via effect on
the phosphorylation state, activity or the nuclear-cytoplasmic distribution of Nrf1/2 proteins. T headed purple line indicates the direct interaction
of SirT1 with SUV39H1 with a repression effect. The red circles designate the genes that expressed higher in H-bc than 5637 cells, while the blue
circles indicate the genes in a reverse state of expression (based on the RNA-seq data, not shown in this paper).
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bladder cancer chemotherapy, including the level of the
miR-193a-3p gene, both LOXL4 and SRSF2 gene and
the key OS pathway associated genes in both cancer tis-
sues and urine sediments.Methods
Cell lines and culture
Five bladder cancer cell lines were purchased from the
Chinese Academy of Cell Resource Center (Shanghai,
China): 5637 (ATCC NO. HTB-9), T24(ATCC NO.
HTB-4), UM-UC-3 (ATCC NO. CRL-1749), Biu87
(established by department of Urology of Beijing Medical
University in 1987 [50]) and H-bc cell lines (established
by cancer research Institute of Kunming Medical Col-
lege, 1986). UM-UC-3 cells are cultured in MEM plus
10% Fetal Bovine serum, and the other cell lines are cul-
tured in RPMI1640 (Invitrogen, USA) + 10% Fetal Bovine
serum (Invitrogen, USA) and 1% glutamine at 37°C in
5% CO2.Chemotherapeutics
The clinic grade of drugs are used (NCI Dictionary
of Cancer Terms, http://www.cancer.gov/dictionary),
Pirarubicin (Pi, Wanle, Shenzhen), Paclitaxel (Pa, Taiji,
Sichuan), Adriamycin (Ad, Pfizer, Jiangsu), Epirubicin
Hydrochloride (EH, Haizheng, Zhejiang), and Cisplatin
(Ci, Haosen, Jiangsu).Chemoresistance profiling (IC50 determination)
Cells at the logarithmic phase of growth were seeded in
triplicate in 96-well plates at a density of 0.5 × 104/well
and treated with 4 fold serious diluted drugs for
72 hours. The cell survival was then measured by a thia-
zolyl blue tetrazolium bromide (MTT, 490 nm reading)-
based cell viability assay [51]. Both the linear regression
parameters and the IC50 (the concentration of drug re-
quired for 50% cells killed) with the no-drug control as
the reference were calculated. The relative chemoresis-
tance was presented as the fold for the IC50 of the cell
lines over the lowest IC50.The reagents for the transient transfection and in vivo
assays
All the mimic, agomiR, antagomiR, siRNA, the scramble
sequence (negative control, NC) and the riboFECT
CP transfection kit were supplied by Ribobio, Guangzhou,
China. Transfection of both ribonucleic acid reagents
mentioned above and the reporter plasmids was per-
formed according to the manufactory’s instruction.
Chemically modified mimic oligonucleotides (agomir)
were synthesized to regulate miR-193a-3p/5p expres-
sion in vivo. The 3’ end of the oligonucleotides was con-
jugated to cholesterol, and all the bases were 2’-OMe
modified. The agomir oligonucleotides were depro-
tected, desalted and purified by high-performance liquid
chromatography.
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A full length of the human LOXL4 3’-untranslated re-
gion (1325 bp) with a wide type and mutant target se-
quence for miR-193a-3p were cloned into 3’ flank of
luciferase coding sequence of pGL3 (Invitrogen, Carls-
bad, CA, USA) to construct pGL3-luc-LOXL4 WT and
pGL3-luc-LOXL4 Mut, respectively. All the constructs
were confirmed by DNA sequencing. Cells were seeded
into 96-well plates at around 1 × 104 cells per well and
transfected with a mixture of 50 ng pGL3-luc-LOXL4
WT or Mut, 5 ng Renilla plus 5 pmol mimic or NC
nucleotides, with the riboFECT CP transfection kit ac-
cording to the manufacturer’s instruction. Both firefly
and Renilla luciferase activities were measured around
18 hours after transfection by the Dual-Luciferase Re-
porter Assay System (Promega, Madison, Wisconsin,
USA) using a Promega GloMax 20/20 luminometer.
The relative firefly luciferase activities were normalized
with the Renilla luciferase activities, which served as
an internal control for transfection efficiency for the
standard analysis.
The signaling pathway analysis
The following five signaling pathway reporter constructs
were obtained from Qiagen (Hilden, German). DNA
damage, Notch, NF-κB, Myc/Max and Oxidative Stress
(OS) pathways and analyzed according to the manufac-
turer’s instruction. Briefly, the cells were transfected in
triplet with each firefly luciferase reporter construct in
combination with the Renilla luciferase based control
construct using the riboFECT CP transfection reagent,
and both luciferase activities in cell extracts at 18 hours
after transfection were measured. The relative luciferase
activities (luciferase unit) of the pathway reporter over
the negative control in the transfected cells were calcu-
lated as a measurement of the pathway activity.
Apoptosis analysis
Cells were harvested and rinsed with PBS twice. Then
5 μl of FITC-labeled enhanced-annexinV and 5 μl
(20 μg/ml) of propidium iodide were added into 100 μl
cell suspension. Upon incubation in the dark for 15 min
at room temperature, samples were diluted with 400 μl
PBS. Flow cytometry was carried out on a FACS calibur
instrument. The result was analyzed according to the
manufacturer’s instruction. The experiments were per-
formed independently three times and a representative
was shown.
RNA analysis
Total RNA was isolated from the cells at the logarithmic
phase by Trizol technology (Tiangen Biotech Co., Ltd.,
Beijing, China). For mRNA analysis, the cDNA primed
by oligo-dT was made with a prime Script RT reagentkit (Tiangen Biotech Co., Ltd., Beijing, China) and the
mRNA level of the genes LOXL4, SRSF2, Nrf-1,Nrf-2,
CDC37, SUV39H1, and NQO1 were quantified by a
duplex-qRT-PCR analysis where the Taqman probes in
a different fluorescence for the β-actin (provided by
Shing Gene, Shanghai, China) was used in the FTC-
3000P PCR instrument (FUNGLYN BIOTECH INC,
Toronto, Canada). Using the 2-ΔΔ Ct method, the
normalization with the β-actin level was performed be-
fore the relative level of the target genes was compared.





































For detecting and quantifying the expression of specific
miRNAs, RNA was reverse transcribed using Bulge-
Loop™ miRNA qRT-PCR Primer Set (Ribobio) and quan-
tified by the SYBR Green-based real-time PCR analysis
in the FTC-3000P (FUNGLYN BIOTECH INC, Canada).
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Ct values of U6 RNA before quantification using the
2-ΔΔCt method.
Western blot analysis of protein
Cells were lyzed with a lysis buffer (60 mM Tris–HCl,
pH6.8, 2% SDS, 20% glycerol, 0.25% bromophenol blue,
1.25% 2-mercaptoethanol) and heated at 100°C for
10 min before the electrophoresis/Western analysis.
The anti-LOXL4 (AP17245b), anti-SRSF2 (AP2800a),
anti-GAPDH (AM1020a), anti-rabbit IgG peroxidase-
conjugated antibody(LP1001b), and HRP goat anti-
mouse IgG antibody (LP1002a) were provided by
Wuxiphama, Shanghai, China. The target bands were re-
vealed by an enhanced chemiluminescence reaction
(Thermo Fisher Scientific. Waltham, MA, USA) and the
relative density (level) of proteins over the GAPDH band
were quantified with the Gel-Pro Analyzer (Media
Cybernetics, Rockville, MD, USA).
The in vivo studies
Animal experiments were undertaken in accordance
with the National Institutes of Health Guide for the Care
and Use of Laboratory Animals. BALB/c male nude mice
of 8–12 weeks of age were used for this study. 5637
or H-bc cells were embedded in BD Matrigel™ Matrix
(Becton, Dickinson, NJ, USA) [52] and subcutaneously
injected into at four sites at back of mice as following:
1.7 × 107 cells/site for 5637, 0.7 × 107 cells/site for
H-bc,4 sites/mouse, 6 mice for 5637, 6 mice for H-bc,
respectively. From the 4th day after cell injection, all
5637 generated tumors on the left back of nude mice
were intratumorally injected with 2nM miR-193a-3p
agomiR/Mock, while H-bc generated tumors on the left
back of nude mice were injected with 4nM miR-193a-3p/
Mock antagomiR. From the 6th day after cell injection, 3
mice from 5637 and 3 from H-bc were intraperitoneally re-
ceived Pa (45 ug/mouse) once in 2 days. The remaining 6
mice (3 from 5637 and 3 from H-bc) received phosphate-
buffered saline (PBS) as a mock treatment control. Mice
were humanely sacrificed on day 25, and the tumors were
weighed and photographed. The tumor weight was de-
scribed as the mean ± S.D.
Expressions of SRSF2, LOXL4, and Ki67 proteins were
measured using immunochemical analysis on 5-mm
slices of formalin fixed paraffin-embedded tumor xeno-
grafts in nude mice. To avoid inter-treatment bias, the
tissue slices from all the six groups were made on a
single slide and subject to the same immuno-staining
simultaneously. Antigens were retrieved by pretreating
dewaxed sections in a microwave oven at 750 watts for
5 min in a citrate buffer (pH 6) processed with the Super
Sensitive Link-Labeled Detection System (Biogenex,
Menarini, Florence, Italy). The enzymatic activities weredeveloped using 3-amino-9-ethylcarbazole (Dako, Milan,
Italy) as a chromogenic substrate. Following counter
staining with Mayer hematoxylin (Invitrogen), slides
were mounted in aqueous mounting medium (glycergel,
Dako). Pictures were taken using LEICA DM 4000B
microscope (Wetzlar, German), while the relative level of
each protein was calculated using LEICA software, per-
centage of the mock over the chemotherapeutic treated
tumors was calculated and plotted.
Statistical analysis
Data are presented as means, and error bars indicate the
S.D. or S.E. All statistical analyses were performed with
Excel (Microsoft, Redmond, WA) or Prism (GraphPad
Software Inc., La Jolla, CA). Two-tailed Student’s t-test,
a one-way analysis of variance or Mann–Whitney U test
was used to calculate statistical significance. A p-value of
<0.05 was considered to be significant.
Additional file
Additional file 1: Figure S1. Immunostaining analysis of tumor tissues
from in vivo study. A, The 5637 and H-bc tumor tissues from each group
were fixed on one slide and immunostained for indicated antibody,
respectively. Levels of Ki67, SRSF2, and LOXL4 proteins in each were
determined by immunostaining. B, Levels of Ki67, SRSF2, and LOXL4
proteins were summarized in the table.
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